New CAR-T therapy aims to outsmart resistant blood cancers
NCT ID NCT07539610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new type of immune cell therapy called Sup19 CAR-T in 9 adults with B-cell acute lymphoblastic leukemia or lymphoma. It is for patients whose cancer stopped responding to previous CD19-targeted treatments or has low levels of CD19. The main goal is to check safety and see if the therapy can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sup19 CAR-T cells (a type of immune cell therapy)
What this could lead to
If it works, this could offer a new treatment option for people with certain blood cancers who have run out of other CD19-targeted therapies.
What could go wrong
This is a very early Phase 1 trial with only 9 participants, so it is too small to prove effectiveness. There are also known risks like severe immune reactions (CRS and ICANS).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology, Chinese Academy of Medical Sciences & Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300000, China